In National Advertising Division Challenge, Fletcher Family Medical Center Voluntarily Discontinues Compounded Sublingual Semaglutide Product Claims
New York, NY – November 13, 2025 – Following a challenge brought by Novo Nordisk Inc., BBB National Programs’ National Advertising Division reviewed express and implied advertising claims made by Fletcher Family Medical Center for its compounded sublingual semaglutide product, Subsema, that appeared on Fletcher’s website.
Fletcher Family Medical Center is a medical center located in Los Angeles, California that advertised and marketed Subsema, a compounded semaglutide product for sublingual administration. Challenger Novo Nordisk is a global pharmaceutical company specializing in diabetes care as well as other chronic conditions including obesity, rare diseases, and cardiovascular conditions. Novo Nordisk markets the only FDA-approved semaglutide medicines, including Rybelsus®, Ozempic® and Wegovy®.
Novo Nordisk challenged Fletcher’s express and implied claims regarding its compounded semaglutide product’s claimed superiority, safety, efficacy, and health benefits.
During the inquiry, Fletcher informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.
Fletcher Family Medical Center is a medical center located in Los Angeles, California that advertised and marketed Subsema, a compounded semaglutide product for sublingual administration. Challenger Novo Nordisk is a global pharmaceutical company specializing in diabetes care as well as other chronic conditions including obesity, rare diseases, and cardiovascular conditions. Novo Nordisk markets the only FDA-approved semaglutide medicines, including Rybelsus®, Ozempic® and Wegovy®.
Novo Nordisk challenged Fletcher’s express and implied claims regarding its compounded semaglutide product’s claimed superiority, safety, efficacy, and health benefits.
During the inquiry, Fletcher informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.